Clinical Trial Update: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Aldesleukin and Pembrolizumab in patients with metastatic or advanced melanoma has been terminated; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2023-02-09